Ceftazidime Injection shortage
Ceftazidime Injection is currently listed in shortage by the FDA. The FDA lists 2 affected products. This page was last refreshed from FDA data on Oct 3, 2026.
Pfizer (Hospira) is permanently stopping production of its ceftazidime injection. Other makers — including Sagent Pharmaceuticals and WG Critical Care — still list ceftazidime injection in 2 g and 6 g strengths, so the medicine remains available from other sources.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Ceftazidime Injection. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Nov 14, 2025Currently in shortage2 of 2 products affected.
-
Nov 14, 2025First reported to the FDA2 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 2 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Tazicef, Injection, 1 g (NDC 0409-5092-16) | — | — | Discontinuation of the manufacture of the drug | — |
| To Be Discontinued | Tazicef, Injection, 2 g (NDC 0409-5093-11) | — | — | Discontinuation of the manufacture of the drug | — |
These rows are manufacturer reports to the FDA for Ceftazidime Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Ceftazidime Injection? options further down this page.
Why is Ceftazidime Injection in shortage?
Hospira (a Pfizer company) has decided to permanently stop making their brand of ceftazidime injection, sold under the name Tazicef. This affects both the 1 gram and 2 gram versions of the product. Because this is a permanent decision — not a temporary delay — these two products will not be coming back from this particular manufacturer.
It's worth noting that Hospira did not share a specific public reason for why they made this business decision to stop manufacturing Tazicef. The FDA shortage report simply reflects that the discontinuation applies to both strengths, and there are no other Hospira/Pfizer strengths or package sizes of this product that are listed as continuing production.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Ceftazidime Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Ceftazidime Injection?
Ceftazidime injection is currently on the FDA drug-shortage list. I want to walk you through what this means and what you can do next.
Both reported strengths — the 1 g and the 2 g — have no available source right now. The reason listed is that the manufacturer, Hospira (a Pfizer company), is discontinuing its production of these products (sold as Tazicef). Because this is a discontinuation rather than a temporary delay, this particular supply problem may be permanent for these items, and there is no estimated-recovery date. This report reflects only the manufacturer that filed it, so it does not mean every company has stopped making this medicine.
In fact, the same medicine — ceftazidime injection — is listed as available from other makers, including Sagent Pharmaceuticals and WG Critical Care, and Hospira also has a 6 g size on record. Your pharmacy may be able to source one of these, though it may not be in local stock.
Here is what I suggest:
- Do not stop, skip, or change your doses on your own. Keep taking your medicine as prescribed.
- Ask your pharmacy to check wholesalers and other manufacturers for the same ceftazidime injection from another maker.
- Because this product is being discontinued, talk with your prescriber or pharmacist about a suitable option going forward.
Manufacturer contact numbers are listed on this page for reference, though pharmacies usually handle those calls. This is general, national information and may not match your local pharmacy's actual stock.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Ceftazidime Injection?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Ceftazidime Injection is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Tazicef | CEFTAZIDIME 2 g/1 | Injection, Powder, For Solution · Intravenous | Hospira, Inc. | 00409-5084-11 |
| Tazicef | CEFTAZIDIME 6 g/1 | Injection, Powder, For Solution · Intravenous | Hospira, Inc. | 00409-5086-11 |
| Ceftazidime | CEFTAZIDIME 2 g/1 | Injection, Powder, For Solution · Intravenous | Sagent Pharmaceuticals | 25021-0128-50 |
| Ceftazidime | CEFTAZIDIME 6 g/30mL | Injection, Powder, For Solution · Intravenous | Sagent Pharmaceuticals | 25021-0129-99 |
| Ceftazidime | CEFTAZIDIME 2 g/1 | Injection, Powder, For Solution · Intravenous | WG Critical Care, LLC | 44567-0236-10 |
| Ceftazidime | CEFTAZIDIME 6 g/1 | Injection, Powder, For Solution · Intravenous | WG Critical Care, LLC | 44567-0237-06 |
Therapeutic equivalents & pricing 8 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Ceftazidime 1 g | Sagent | 25 vials | $3.704 | AP | Availability likely |
| Ceftazidime 1 g | WG | 25 vials | $3.704 | AP | Availability likely |
| Tazicef 1 g | Hospira, | 25 vials | — | AP | Discontinued |
| Tazicef 1 g | Hospira, | 25 vials | — | AP | Discontinued |
| Tazicef 2 g | Hospira, | 10 vials | — | AP | Discontinued |
| Tazicef 2 g | Hospira, | 10 vials | — | AP | Discontinued |
| Ceftazidime 2 g | Sagent | 10 vials | — | AP | Discontinued |
| Ceftazidime 2 g | WG | 10 vials | — | AP | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Ceftazidime Injection — that fall in the same broad treatment class (cephalosporin antibiotics - 3rd generation) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other anti-infective shortages
Ceftazidime Injection shortage FAQs
Is Ceftazidime Injection in shortage?
Which products are affected?
When will Ceftazidime Injection be available again?
Can I still get Ceftazidime somewhere?
What should I do if I take Ceftazidime Injection?
Still have a question about the Ceftazidime Injection shortage?
Ask a pharmacist about this shortage →View Ceftazidime Injection on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.